在固体瘤中对瘤病毒M1的TAMs介导的耐药性
Xuanming Liang1, Jingjie Li2, Jiehong Chen1
1Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
Journal for immunotherapy of cancer
|November 14, 2025
概括
向与瘤相关的巨细胞 (TAMs) 增强了瘤性病毒M1 (OVM) 对固体瘤的疗效. 削减TAMs可以提高病毒载量和CD8+T细胞反应,克服OVM抵抗力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 病毒学 病毒学
背景情况:
- 瘤病毒M1 (OVM) 通过免疫细胞死亡和CD8+T细胞激活显示出抗瘤潜力.
- 在体内,OVM的疗效是可变的,耐药性机制尚不清楚.
- 与瘤相关的巨细胞 (TAMs) 是免疫抑制的,可能会限制OVM治疗.
研究的目的:
- 调查TAMs在OVM电阻中的作用.
- 为了确定TAM耗尽是否增强OVM抗瘤活性.
- 阐明TAM介导的OVM阻力背后的机制.
主要方法:
- 利用结直肠,胰腺,前列腺和黑色素瘤癌症的综合基因小鼠模型.
- 使用克洛德罗纳酸脂质体或CSF1R抗体的贫乏TAMs.
- 评估病毒载量,免疫细胞透 (流/质细胞计) 和基因表达 (RT-qPCR,RNA-seq).
主要成果:
- TAM透与OVM阻力正相关.
- TAM 枯竭增加了内病毒载量和CD8+ T 细胞反应 (GZMB+).
- 在TAM耗尽后,RNA-seq揭示了增强的抗病毒和T细胞通路; CD8+ T细胞耗尽取消了治疗益处.
结论:
- TAMs,特别是M1类子集,通过限制病毒持久性和抑制CD8+T细胞免疫力来调解OVM耐药性.
- 向TAM显著提高了OVM在固体瘤中的抗瘤疗效.
- 涉及TAM向剂的组合策略对增强瘤性病毒疗法充满希望.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.6K
08:51Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
9.4K
相关概念视频
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K